Equity Method Investment and Other Equity Investments - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended		2 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 30, 2024	Mar. 31, 2024	Feb. 29, 2024	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Schedule Of Equity Method Investments [Line Items]
Unrealized gain on ongoing mark-to-market adjustments of investment in equity security					$ 0	$ (203)	$ 0	$ (6,397)
Gain from diconsolidation					126,294	0	126,294	0
Loss from equity method investment					(7,925)	0	(7,925)	0
Prepaid expenses and other current assets				$ 28,396	28,396		28,396		$ 24,305	[1]
Research and development liabilities					114,695	107,488	255,667	200,349
Fair value of warrants									$ 1,600
Realized losses recognized on investment in equity securities					0	1,638	8,136	8,796
LianBio | Equity Method Investee's IPO
Schedule Of Equity Method Investments [Line Items]
Unrealized gain on ongoing mark-to-market adjustments of investment in equity security						$ 1,600		$ 3,200
Bridge Bio Pharma Limited Liability Company | LianBio
Schedule Of Equity Method Investments [Line Items]
Common stock held							5,350,361
Net proceeds received as special cash dividends		$ 25,700
Realized net gains from investment		$ 1,800
Bridge Bio Pharma Limited Liability Company | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd | LianBio
Schedule Of Equity Method Investments [Line Items]
Warrants to purchase common stock									347,569
Warrants exercised			347,569
BridgeBio Oncology Therapeutics
Schedule Of Equity Method Investments [Line Items]
Payment for private equity financing with external investors					200,000
BridgeBio Oncology Therapeutics | TheRas, Inc
Schedule Of Equity Method Investments [Line Items]
Payment for private equity financing with external investors	$ 200,000
Percentage of ownership reduced for private equity financing	37.90%
Gain from diconsolidation					126,300		$ 126,300
Equity investment	$ 124,900			124,900	124,900		124,900
Difference of between fair value of equity investment and underlying equity in net assets				49,600	49,600		49,600
Loss from equity method investment				7,900
Aggregate carrying amount of equity method investment				117,000	117,000		117,000
BridgeBio Oncology Therapeutics | TheRas, Inc | Transition Service Aggrement
Schedule Of Equity Method Investments [Line Items]
Prepaid expenses and other current assets				$ 100	100		100
Other income					800		800
Research and development liabilities					$ 300		300
Accrued research and development expenses							300
PellePharm, Inc
Schedule Of Equity Method Investments [Line Items]
Realized losses recognized on investment in equity securities							$ 1,200

[1] The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date.